Ülfer, Gözde2024-01-172024-01-172023Ülfer, G. (2023). Quantitative measurement of HER2/neu oncogene amplification and p53 tumor suppressor gene deletion by RT-PCR in breast cancer. Experimed, 13(3), 257-262. https://dx.doi.org/10.26650/experimed.13749592667-5846https://dx.doi.org/10.26650/experimed.1374959https://hdl.handle.net/20.500.12511/12158Objective: The aim of the study was to quantitatively evaluate HER2/neu oncogene amplification and p53 tumor suppressor gene deletion in breast cancer with real-time polymerase chain reaction (RT-PCR). Materials and Methods: Sections obtained from the tumor tissues of 50 patients were paraffinized on slides, and DNA extraction was performed. HER2/neu amplification and p53 deletion were analyzed using RT-PCR with respect to immunohistochemistry (IHC). Results: For 25 patients with breast cancer, we compared IHC and RT-PCR results for the quantitative measurement of HER2/neu expression. We found a significant correlation between the results obtained using IHC and RT-PCR (p < 0.05). Taking the results of IHC as reference, the sensitivity and specificity of the RT-PCR method were 57% and 83%, respectively. HER2/neu amplification and p53 deletion did not have a significant correlation with tumor size, histological grade, lymph node invasion, and status of estrogen receptor and progesterone receptor (p>0.05, for all). Conclusion: RT-PCR measured gene levels reliably and accurately with high sensitivity and specificity, making it superior to IHC, which is subjective.eninfo:eu-repo/semantics/openAccessBreast CancerHER2/neup53RT-PCRArticle13325726210.26650/experimed.1374959Q4WOS:0013220334000102-s2.0-85180920115Q4